Patents Assigned to Scotia Holdings PLC
-
Publication number: 20040071762Abstract: Niacin in the form of a topical preparation, both as such and when incorporated in devices for application to the skin; the devices themselves; diagnosis or monitoring of schizophrenia using the preparations or devices; and manufacture of medicaments for such monitoring and diagnosis.Type: ApplicationFiled: March 10, 2003Publication date: April 15, 2004Applicant: Scotia Holdings PLCInventors: Alexander Iain Munro Glen, Pauline Elizabeth Ward, David Frederick Horrobin
-
Publication number: 20040048927Abstract: This invention relates to the treatment of a disorder selected from the group consisting of Alzheimer's disease and other dementias, and tardive dyskinesia by administering a composition of essential fatty acids of eicosapentaenoic acid (EPA) and stearidonic acid (SA).Type: ApplicationFiled: July 11, 2003Publication date: March 11, 2004Applicant: Scotia Holdings PLCInventor: David Frederick Horrobin
-
Publication number: 20040014810Abstract: A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present.Type: ApplicationFiled: May 2, 2003Publication date: January 22, 2004Applicant: Scotia Holdings PLC.Inventor: David Frederick Horrobin
-
Patent number: 6624195Abstract: This invention relates to the treatment of depression by administering a composition of essential fatty acids of eicosapentaenoic (EPA) and steraridonic (SA) acids.Type: GrantFiled: September 18, 2001Date of Patent: September 23, 2003Assignee: Scotia Holdings PLC.Inventor: David Frederick Horrobin
-
Patent number: 6610740Abstract: A nutritional, cosmetic or pharmaceutical formulation comprising esters of polyethylene glycol in which the polyethylene glycol chain is terminated at one end by a polyunsaturated fatty acyl group, preferably C18-C22 and at the other end by a C1-C4 alkyl group, preferably a methyl group.Type: GrantFiled: November 12, 1998Date of Patent: August 26, 2003Assignee: Scotia Holdings PLCInventors: Paul Andrew Wakefield, Philip Knowles, Mehar Singh Manku, David Frederick Horrobin
-
Patent number: 6555700Abstract: The invention relates to compounds of formula: wherein R1 is selected from the group consisting of fatty acid acyl groups of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, and wherein R2 is selected from the group consisting of H, fatty acid acyl of 12 to 30 carbon atoms and fatty alcohol groups of 12 to 30 carbon atoms, the same as or different from R1, and the residue of a nutrient, drug, or other bioactive compound, and to the use of these compounds to deliver drugs and other bioactive compounds.Type: GrantFiled: January 28, 1998Date of Patent: April 29, 2003Assignee: Scotia Holdings plcInventors: David Frederick Horrobin, Mehar Manku, Austin McMordie, Philip Knowles, Peter Redden, Andrea Pitt, Paul Bradley, Paul Wakefield
-
Publication number: 20030045578Abstract: A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present.Type: ApplicationFiled: September 18, 2001Publication date: March 6, 2003Applicant: SCOTIA HOLDINGS PLCInventor: David Frederick Horrobin
-
Patent number: 6517883Abstract: A food composition giving a prolonged feeling of satiety, comprising a mixture of or an oil-in-water emulsion of triglyceride oils having a solid fat content at ambient or body temperature with a food emulsifier. The invention also refers to the use of said mixture or oil-in-water emulsion for the preparation of a pharmaceutical composition for the control of calorie or fat intake.Type: GrantFiled: January 6, 2000Date of Patent: February 11, 2003Assignee: Scotia Holdings PLCInventors: Bengt Herslof, Lars Lindmark, Karin Bohlinder, Anders Carlsson
-
Publication number: 20020065319Abstract: A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present.Type: ApplicationFiled: September 18, 2001Publication date: May 30, 2002Applicant: SCOTIA HOLDINGS PLCInventor: David Frederick Horrobin
-
Patent number: 6331568Abstract: A pharmaceutical preparation for the treatment of schizophrenia and/or tardive dyskinesia using an oil comprising eicosapentaenoic acid (EPA) and/or stearidonic acid (SA) in amounts of more than 20%, preferably more than 40% and very preferably more than 70% by weight of the total (preferably of the total unsaturated) fatty acids present.Type: GrantFiled: June 10, 1999Date of Patent: December 18, 2001Assignee: Scotia Holdings PLC.Inventor: David Frederick Horrobin
-
Patent number: 6245811Abstract: Compounds of structure (I), and when for use in therapy: where R1 is an acyl group derived from a C16-30 fatty acid with two or more cis or trans double bonds and particularly an n-6 or n-3 series EFA or conjugated linoleic acid, or columbinic acid, or parinaric acid and R2 is as R1 the same or different, or any other nutrient, drug or other bioactive residue released as the active in the body and R3 is either hydrogen, fully hydrocarbon, or containing heteroatoms, preferably an alkyl group particularly a C1-C4 alkyl group.Type: GrantFiled: August 18, 1999Date of Patent: June 12, 2001Assignee: Scotia Holdings PLCInventors: David Frederick Horrobin, Mehar Manku, Austin McMordie, Philip Knowles, Peter Redden, Andrea Pitt
-
Patent number: 6184251Abstract: This invention relates to the administration of arachidonic acid or docosahexaenoic acid or precursors thereof to children or pregnant women for the treatment or prevention of dyspraxia.Type: GrantFiled: February 4, 2000Date of Patent: February 6, 2001Assignee: Scotia Holdings PLCInventors: Barbara Jacqueline Stordy, David F. Horrobin
-
Patent number: 6177470Abstract: Optimum conditions for prostaglandin synthesis are provided by internally administering an ascorbic-6-acid ester of gamma-linolenic acid or an ascorbic-6-acid ester of dihomo-gamma-linolenic acid.Type: GrantFiled: March 2, 1998Date of Patent: January 23, 2001Assignee: Scotia Holdings PLCInventors: David F Horrobin, Philip Knowles, Mehar S Manku
-
Patent number: 6069168Abstract: Use of 6-desaturated n-6 fatty acids, especially gammalinolenic acid (GLA), dihomogammalinolenic acid (DGLA) or arachidonic acid (AA), together with a pharmaceutically acceptable material reducing intracellular levels of sorbitol in the body, particularly an aldose reductase inhibitor, in the treatment of (including prophylactic treatment), and in the preparation of medicaments for the treatment of (including prophylactic treatment), the long-term complications of diabetes mellitus. Pharmaceutical compositions of said materials. The ascorbate esters of 6-desaturated n-6 fatty acids (other than GLA or DGLA) per se.Type: GrantFiled: February 6, 1997Date of Patent: May 30, 2000Assignee: Scotia Holdings PlcInventors: David Frederick Horrobin, Mary Cotter, Norman Cameron
-
Patent number: 5990164Abstract: An N-alkylpolyhydroxyamine salt of an n-6 or n-3 essential fatty acid (EFA) that is beyond the 6-desaturation step, or of any polyunsaturated fatty acid, other than those belonging to the n-6 and n-3 series, having 16 to 26 carbon atoms and up to six double bonds, the double bonds being in the cis or trans configuration, the salt being formed with the fatty acid either as such or in the form of a covalent derivative, through the carboxyl group, of a bifunctional compound itself having a free acid function.Type: GrantFiled: March 17, 1998Date of Patent: November 23, 1999Assignee: Scotia Holdings PLCInventors: David F. Horrobin, Philip Knowles, Mehar Manku, John C. Stewart
-
Patent number: 5922345Abstract: Countering side effects of parenteral or fluid-diet enteral nutrition by adding one or more 6-desaturated essential fatty acids (EFAs) to parenteral or enteral composition (particularly low-fat compositions) being given, or giving them in addition to the compositions.Type: GrantFiled: January 11, 1996Date of Patent: July 13, 1999Assignee: Scotia Holdings PlcInventors: David F. Horrobin, Lars Lindmark
-
Patent number: 5888541Abstract: Increase gut calcium absorption in humans or animals by the administration of GLA, DGLA or LA as such or in salt or other pharmacologically acceptable form, optionally in association with EPA, DHA or other EFA in similar forms, specifically useful in the treatment of osteoporosis.Type: GrantFiled: January 15, 1997Date of Patent: March 30, 1999Assignee: Scotia Holdings PLCInventors: David F. Horrobin, Brenda E. Reynolds
-
Patent number: 5871757Abstract: Polyunsaturated oils such as triply or higher ethylenically unsaturated organic materials are stabilized against ambient temperature atmospheric oxidation by the addition of an essential oil such as thyme oil, oregano oil, pepper oil or clove oil.Type: GrantFiled: October 16, 1996Date of Patent: February 16, 1999Assignee: Scotia Holdings PLCInventors: John B. Cloughley, David F Horrobin
-
Patent number: 5866703Abstract: Triglycerides with at least two different acids chosen from 6-desaturated essential fatty acids and oleic acid, useful in nutrition and in medicine.Type: GrantFiled: October 16, 1995Date of Patent: February 2, 1999Assignee: Scotia Holdings PLCInventors: David F. Horrobin, Austin McMordie, Mehar Singh Manku, Philip Knowles
-
Patent number: 5859055Abstract: Gamma-linolenic acid and/or dihomo-gamma-linolenic acid is used in the preparation of a medicament for inhibiting reocclusion of an artery from which an occlusion or other blockage has been removed, or for preventing occlusion of peripheral or coronary arteries. The medicament may also comprise eicosapentaenoic acid.Type: GrantFiled: November 14, 1995Date of Patent: January 12, 1999Assignee: Scotia Holdings PLCInventors: David F. Horrobin, John C. M. Stewart